
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Portland, Ore. - The topical immunomodulator pimecrolimus cream 1 percent (ASM 981, Elidel) significantly reduces flares without systemic adverse events in children with atopic dermatitis, according to researchers.